Triple Treatment Combo Beneficial in BRAF - Mutant CRC

Irinotecan, cetuximab, and vemurafenib improve progression - free survival in BRAFV600E - mutated colorectal cancer
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Gastroenterology, Oncology, Pathology, Pharmacy, Journal, Source Type: news